Snehal Shukla

Dr. Snehal Shukla

Pfizer (United States), New York, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya
VPVineela Parvathaneni
Vineela Parvathaneni
NKNishant S. Kulkarni
Nishant S. Kulkarni
Snehal ShuklaSnehal Shukla
Snehal Shukla
JDJenna K. Damon
Jenna K. Damon
Vivek GuptaVivek Gupta
Vivek Gupta

1 December 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
XWXuechun Wang
Xuechun Wang
VPVineela Parvathaneni
Vineela Parvathaneni
Snehal ShuklaSnehal Shukla
Snehal Shukla
NKNishant S. Kulkarni
Nishant S. Kulkarni
AMAaron Muth
Aaron Muth
Vivek GuptaVivek Gupta
Vivek Gupta

18 September 2017 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
DSDeepak Solomon
Deepak Solomon
NGNilesh Gupta
Nilesh Gupta
NMNihal S. Mulla
Nihal S. Mulla
Snehal ShuklaSnehal Shukla
Snehal Shukla
YGYadir A. Guerrero
Yadir A. Guerrero
Vivek GuptaVivek Gupta
Vivek Gupta

28 February 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
VPVineela Parvathaneni
Vineela Parvathaneni
NKNishant S. Kulkarni
Nishant S. Kulkarni
Snehal ShuklaSnehal Shukla
Snehal Shukla
PFPamela T. Farrales
Pamela T. Farrales
Nitesh KundaNitesh Kunda
Nitesh Kunda
Vivek GuptaVivek Gupta
Vivek Gupta
Non-small cell lung cancer (NSCLC) is a global disorder, treatment options for which remain limited with resistance development by cancer cells and off-target events being major roadblocks for current therapies. The discovery of new drug molecules remains time-consuming, expensive, and prone to failure in safety/efficacy studies. Drug repurposing (i.e., investigating FDA-approved drug molecules for use against new indications) provides an opportunity to shorten the drug development cycle. In this project, we propose to repurpose pirfenidone (PFD), an anti-fibrotic drug, for NSCLC treatment by encapsulation in a cationic liposomal carrier. Liposomal formulations were optimized and evaluated for their physicochemical properties, in-vitro aerosol deposition behavior, cellular internalization capability, and therapeutic potential against NSCLC cell lines in-vitro and ex-vivo. Anti-cancer activity of PFD-loaded liposomes and molecular mechanistic efficacy was determined through colony formation (1.5- to 2-fold reduction in colony growth compared to PFD treatment in H4006, A549 cell lines, respectively), cell migration, apoptosis and angiogenesis assays. Ex-vivo studies using 3D tumor spheroid models revealed superior efficacy of PFD-loaded liposomes against NSCLC, as compared to plain PFD. Hence, the potential of inhalable liposome-loaded pirfenidone in NSCLC treatment has been established in-vitro and ex-vivo, where further studies are required to determine their efficacy through in vivo preclinical studies followed by clinical studies.

28 October 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Snehal ShuklaSnehal Shukla
Snehal Shukla
NKNishant Kulkarni
Nishant Kulkarni
ACAmanda Chan
Amanda Chan
VPVineela Parvathaneni
Vineela Parvathaneni
PFPamela Farrales
Pamela Farrales
Vivek GuptaVivek Gupta
Vivek Gupta
This study aimed at developing metformin hydrochloride (Met) encapsulated liposomal vesicles for enhanced therapeutic outcomes at reduced doses against breast cancer. Liposomal Met was prepared using thin-film hydration through various loading methods; passive loading, active loading, and drug-loaded lipid film. The drug-loaded film method exhibited maximum entrapment efficiency (~65%) as compared to active loading (~25%) and passive loading (~5%) prepared Met-loaded liposomes. The therapeutic efficacy of these optimized liposomes was evaluated for cellular uptake, cytotoxicity, inhibition of metastatic activity, and apoptosis-inducing activity. Results demonstrated significantly superior activity of positively charged liposomes resulting in reduced IC50 values, minimal cell migration activity, reduced colony formation, and profound apoptosis-induced activity in breast cancer cells as compared to Met. The anti-tumor activity was investigated using a clinically relevant in vitro tumor simulation model, which confirmed enhanced anti-tumorigenic property of liposomal Met over Met itself. To the authors’ knowledge, this is the first report of Met-loaded liposomes for improving the efficacy and therapeutic effect of Met against breast cancer. With the results obtained, it can be speculated that liposomal encapsulation of metformin offers a potentially promising and convenient approach for enhanced efficacy and bioavailability in breast cancer treatment.

1 March 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
BVBhuvaneshwar Vaidya
Bhuvaneshwar Vaidya
NKNishant S. Kulkarni
Nishant S. Kulkarni
Snehal ShuklaSnehal Shukla
Snehal Shukla
VPVineela Parvathaneni
Vineela Parvathaneni
GCGautam Chauhan
Gautam Chauhan
Vivek GuptaVivek Gupta
Vivek Gupta